Daniel Lee, MD
Interventional Cardiology · Saginaw, MINPI 1861472367
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $167,385 of the $189,971 with a category attached, or 88.1%. 38 manufacturers reported payments, led by Amgen at 54.1% of the total. Reporting peaked in 2021 at $47,192 and has fallen 65.0% since, to $16,524 in 2025. Among interventional cardiology clinicians in MI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 712 payments — averaging $266.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$103K
- Johnson & Johnson$61K
- AstraZeneca$16K
- Medtronic$2K
- Philips North America LLC$1K
- Novartis$1K
- plus $6K from 32 others
Across 88 payments — averaging $1418.89 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$65K
- AstraZeneca$36K
- Amgen$12K
- Biotronik Inc.$11K
- Novartis$2K
- Boehringer Ingelheim International GmbH$350
What the payments were for
- Consulting fees$3000%
- Speaking & faculty fees$167,38588%
- Travel & lodging$7,0834%
- Food & beverage$14,5228%
- Education$6810%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 157 | $102,819 |
| Johnson & Johnson | 156 | $61,127 |
| AstraZeneca | 49 | $15,628 |
| Medtronic | 8 | $1,992 |
| Philips North America LLC | 4 | $1,281 |
| Novartis | 86 | $1,044 |
| Abbott | 31 | $965 |
| Boehringer Ingelheim | 32 | $590 |
| Pfizer | 31 | $538 |
| Bayer | 20 | $476 |
| E.r. Squibb & Sons, L.L.C. | 21 | $394 |
| Edwards Lifesciences | 6 | $364 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 20 | $323 |
| Astellas Pharma US Inc | 8 | $299 |
| Actelion Pharmaceuticals US, Inc. | 8 | $207 |
| Abiomed | 3 | $207 |
| Shockwave Medical, Inc | 3 | $200 |
| Merck | 11 | $183 |
| Lexicon Pharmaceuticals, Inc. | 4 | $172 |
| Kowa Pharmaceuticals America, Inc. | 13 | $172 |
| Amarin Pharma, Inc. | 9 | $153 |
| Kiniksa Pharmaceuticals, Ltd. | 5 | $145 |
| Terumo Medical Corporation | 3 | $125 |
| W. L. Gore & Associates, Inc. | 1 | $121 |
| Esperion Therapeutics, Inc. | 5 | $81 |
| Sanofi-aventis U.S. LLC | 4 | $68 |
| EKOS Corporation | 1 | $54 |
| Lundbeck LLC | 2 | $45 |
| Inari Medical, Inc. | 1 | $32 |
| Kestra Medical Technology Services, Inc. | 1 | $26 |
| Osprey Medical Inc | 2 | $24 |
| Amryt Pharma Holdings Ltd | 1 | $21 |
| Novo Nordisk | 1 | $20 |
| Lilly USA, LLC | 1 | $17 |
| Alnylam Pharmaceuticals Inc. | 1 | $17 |
| Teleflex LLC | 1 | $16 |
| Baylis Medical Company Inc | 1 | $14 |
| ZOLL Circulation Inc | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Repatha$100,096
- XARELTO$58,683
- FARXIGA$14,622
- PRO CV$1,401
- (6574) Coronary Other$1,178
- Azure$273
- Edwards SAPIEN 3 Transcatheter Heart Valve$250
- Visia AF$153
- Inpefa$125
- XIENCE SIERRA$125
- CARDIOFORM Septal Occluder$121
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$114
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$100
How this compares
$189,971 in reported general payments places this provider in the 90th percentile of 187 interventional cardiology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 453 | $583,406 |
| AdempasRiociguat | 32 | $444,874 |
| EliquisApixaban | 263 | $329,769 |
| Repatha SureclickEvolocumab | 305 | $327,729 |
| OpsumitMacitentan | 12 | $151,394 |
| EntrestoSacubitril/Valsartan | 87 | $117,744 |
| FarxigaDapagliflozin Propanediol | 68 | $100,502 |
| JardianceEmpagliflozin | 53 | $85,524 |
| Repatha SyringeEvolocumab | 40 | $38,584 |
| MultaqDronedarone Hcl | 17 | $30,958 |
| BrilintaTicagrelor | 32 | $23,813 |
| Praluent PenAlirocumab | 22 | $16,123 |
| Rosuvastatin Calcium | 663 | $14,898 |
| Atorvastatin Calcium | 707 | $13,004 |
| Ezetimibe | 184 | $4,634 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $61,127 | $583,406453 claims |
| BayerAdempas | $476 | $444,87432 claims |
| PfizerEliquis | $538 | $329,769263 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $207 | $151,39412 claims |
| AstraZenecaFarxiga, Brilinta | $15,628 | $124,315100 claims |
| NovartisEntresto | $1,044 | $117,74487 claims |
| Boehringer IngelheimJardiance | $590 | $85,52453 claims |
| Sanofi-aventis U.S. LLCMultaq | $68 | $30,95817 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 187 interventional cardiology providers in Michigan.
Other interventional cardiology in Saginaw
- Safwan KassasSaginaw$340K
- Amer KadriSaginaw$42K
- Amir KakiDetroit$1.8M
- Tamam MohamadDetroit$960K
- Paul GrossmanAnn Arbor$630K
- Jason RicciPetoskey$594K
- Tim FischellKalamazoo$468K
- Mir BasirDetroit$442K
- Amr AbbasBerkley$416K
- Vishal GuptaKalamazoo$293K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.